This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Investigators from multiple institutions conducted a randomized, placebo-controlled trial to study the long-term efficacy and safety of inhaled budesonide for the prevention of bronchopulmonary dysplasia (BPD) in extremely premature infants. Infants were included if they were born between a gestational age of 23 weeks 0 days and 27 weeks 6 days and required any form of positive-pressure respiratory support. Participants were randomly assigned to receive either placebo or 2 puffs (200 μg per puff) of budesonide every 12 hours in the first 14 days of life followed by 1 puff administered every 12 hours from …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Related Articles
Cited By...
- No citing articles found.